Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
PLoS One ; 13(9): e0203678, 2018.
Article in English | MEDLINE | ID: mdl-30204794

ABSTRACT

Yifei Tongluo (YFTL) is a traditional Chinese medicine (TCM) formulation which has been shown clinical efficacy in treatment of patients with multidrug-resistant tuberculosis in China. However, the underlying mechanisms of the effects of YFTL are lacking. This study investigated the effects of YFTL on immune regulation with a mouse lung infection model with Bacille Calmette-Guérin (BCG). We found that compared with untreated mice, the lung mycobacterial load in YFTL-treated mice was significantly reduced, accompanied by alleviated pulmonary inflammation with reduction of pro-inflammatory cytokines and increase of prostaglandin E2 (PGE2). Flow cytometry analyses showed that Th1 cells were significantly higher in the lungs of YFTL-treated mice at early infection time. The results suggest that YFTL-treatment down-regulates pulmonary inflammation, which facilitates a rapid infiltration of Th1 cells into the lungs. Moreover, the Th1 cells in the lungs were resolved faster at later time concomitant with increased the regulatory T cells (Tregs). The reduction of mycobacterial burden associated with improved tissue pathology, faster Th1 cell trafficking, and accelerated resolution of Th1 cells in the lungs of YFTL-treated mice indicates that YFTL improves mycobacterial clearance by maintaining lung homeostasis and dynamically regulating T cells in the lung parenchyma, and suggests that YFTL can be used as host-directed therapies that target immune responses to mycobacterial infection.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Mycobacterium Infections/immunology , Th1 Cells/drug effects , Tuberculosis, Pulmonary/immunology , Animals , Antibodies, Bacterial/blood , Cytokines/analysis , Cytokines/metabolism , Dinoprostone/metabolism , Disease Models, Animal , Drugs, Chinese Herbal/therapeutic use , Female , Lung/pathology , Medicine, Chinese Traditional , Mice , Mice, Inbred C57BL , Mycobacterium/pathogenicity , Mycobacterium Infections/drug therapy , Mycobacterium Infections/pathology , Spleen/drug effects , Spleen/immunology , Spleen/metabolism , Th1 Cells/cytology , Th1 Cells/immunology , Th1 Cells/metabolism , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/pathology
2.
J Dermatol ; 42(10): 992-5, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26017241

ABSTRACT

Mycobacterium haemophilum is a slow-growing non-tuberculous mycobacterium that is rarely known to cause human skin infection, particularly in immunocompromised patients. We recently experienced a 69-year-old Japanese woman with this infection who had been under immunosuppressive treatment for recalcitrant rheumatoid arthritis. The patient showed disseminated erythematous plaques and subcutaneous nodules on the face and extremities, and interestingly, the face manifested with a striking "facies leontina" appearance. Biopsy revealed abscess and granulomatous dermatitis with the involvement of peripheral nerve bundles and the presence of innumerable acid-fast bacilli, thus necessitating differentiation from lepromatous leprosy. M. haemophilum was identified by molecular characterization as well as by successful culture with iron supplements. Although drug susceptibility testing indicated responsiveness to multiple antibiotics administrated simultaneously for the treatment, it took over 6 months to achieve significant improvement, and we also employed concurrent oral potassium iodide administration and repeated surgical excision. This case highlights the importance of continuous combination therapy for successful outcome in this rare infection. Furthermore, application of potassium iodide for mycobacterial infection warrants further evaluation by accumulating more cases.


Subject(s)
Leprosy/diagnosis , Mycobacterium Infections/diagnosis , Mycobacterium haemophilum/isolation & purification , Aged , Diagnosis, Differential , Face/pathology , Female , Humans , Mycobacterium Infections/pathology , Mycobacterium Infections/therapy
3.
Indian J Med Microbiol ; 32(4): 438-9, 2014.
Article in English | MEDLINE | ID: mdl-25297033

ABSTRACT

Intravesical instillation of Bacillus Calmette-Guerin (BCG) is the treatment of choice for superficial bladder carcinoma. Disseminated BCG infection presenting as granulomatous hepatitis or pneumonitis is a very rare complication of this treatment. Here we report a case series of seven patients previously treated with BCG presenting with pneumonitis. In two of the cases, identification of Mycobacterium bovis was achieved with molecular methods.


Subject(s)
Biological Therapy/adverse effects , Biological Therapy/methods , Carcinoma/therapy , Mycobacterium Infections/microbiology , Mycobacterium bovis/isolation & purification , Pneumonia/microbiology , Urinary Bladder Neoplasms/therapy , Aged , Humans , Lung/pathology , Male , Mycobacterium Infections/pathology , Pneumonia/pathology , Radiography, Thoracic , Tomography, X-Ray Computed
5.
J Vet Med Sci ; 76(5): 705-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24419874

ABSTRACT

A 4-year-old spayed female ferret presented with a 2-month history of anorexia, vomiting and occasional diarrhea. Abdominal ultrasonography revealed thickening of the gastric wall and enlarged abdominal lymph nodes. Biopsy samples from the thickened gastric wall, enlarged abdominal lymph nodes and liver were taken during an exploratory laparotomy. Based on the histopathological examination, mycobacterium infection was diagnosed. The bacterial species could not be identified by additional diagnostic tests of feces, including fecal smear, culture and polymerase chain reaction (PCR). The ferret was treated with prednisolone and multiple antimicrobials, including rifampicin, azithromycin and enrofloxacin, but did not improve with treatment and died 220 days after the first presentation.


Subject(s)
Anti-Infective Agents/therapeutic use , Ferrets/microbiology , Mycobacterium Infections/drug therapy , Mycobacterium Infections/pathology , Animals , Azithromycin/therapeutic use , Enrofloxacin , Fatal Outcome , Female , Fluoroquinolones/therapeutic use , Hematocrit/veterinary , Histological Techniques/veterinary , Laparotomy/veterinary , Leukocyte Count/veterinary , Mycobacterium Infections/surgery , Prednisolone/therapeutic use , Rifampin/therapeutic use
6.
J Antimicrob Chemother ; 69(4): 1057-64, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24222613

ABSTRACT

OBJECTIVES: Of the non-tuberculous mycobacteria, Mycobacterium abscessus is particularly refractory to antimicrobial therapy and new agents with activity against these pathogens are urgently needed. The screening of candidate antimicrobial agents against M. abscessus requires a relevant and reproducible animal model of chronic infection. Granulocyte-macrophage colony-stimulating factor knockout (GM-CSF KO) mice were used to develop a new animal model of chronic pulmonary M. abscessus infection that can be used for preclinical efficacy testing of antimicrobial drugs. METHODS: GM-CSF KO mice were infected with a clinical isolate of M. abscessus via intrapulmonary aerosol delivery using a microsprayer device. The clinical condition, histology and cfu of M. abscessus-infected GM-CSF KO mice were evaluated over a period of 4 months. Mice were treated with azithromycin (100 mg/kg) by oral gavage and the clinical condition, histology and bacterial burden was determined after 2 weeks of treatment. RESULTS: We show that pulmonary infection of GM-CSF KO mice with M. abscessus results in a chronic pulmonary infection that lends itself to preclinical testing of new antimicrobial drugs against this bacterium. Azithromycin treatment of M. abscessus-infected GM-CSF KO mice resulted in a lower bacterial burden in the lungs and spleen, weight gain and significant improvement in lung pathology. CONCLUSIONS: Intrapulmonary aerosol infection of GM-CSF KO mice with M. abscessus is a useful animal model for studying pathogenesis as well as pre-clinical testing of new compounds against M. abscessus in acute or chronic phases of infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/deficiency , Mycobacterium Infections/drug therapy , Mycobacterium/drug effects , Pneumonia, Bacterial/drug therapy , Animals , Bacterial Load , Chronic Disease , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Histocytochemistry , Lung/microbiology , Lung/pathology , Mice , Mice, Knockout , Mycobacterium Infections/microbiology , Mycobacterium Infections/pathology , Pneumonia, Bacterial/microbiology , Pneumonia, Bacterial/pathology , Spleen/microbiology
7.
Transpl Infect Dis ; 13(1): 33-7, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20534038

ABSTRACT

Mycobacterium haemophilum is a slow-growing nontuberculous mycobacterium that can cause disease in both immunocompetent and immunocompromised patients. The most common clinical presentations of infection are the appearance of suppurative and ulcerated skin nodules. For the diagnosis, samples collected from suspected cases must be processed under the appropriate conditions, because M. haemophilum requires lower incubation temperatures and iron supplementation in order to grow in culture. In this case report, we describe the occurrence of skin lesions in a kidney transplant recipient, caused by M. haemophilum, associated with acupuncture treatment. The diagnosis was established by direct smear and culture of material aspirated from cutaneous lesions. Species identification was achieved by characterization of the growth requirements and by partial sequencing of the hsp65 gene. The patient was successfully treated with clarithromycin and ciprofloxacin for 12 months. Considering that the number of patients receiving acupuncture treatment is widely increasing, the implications of this potential complication should be recognized, particularly in immunosuppressed patients.


Subject(s)
Acupuncture Therapy/adverse effects , Kidney Transplantation/adverse effects , Mycobacterium Infections/microbiology , Mycobacterium haemophilum/isolation & purification , Skin Diseases, Bacterial/microbiology , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/therapeutic use , Clarithromycin/therapeutic use , Humans , Immunocompromised Host , Male , Middle Aged , Mycobacterium Infections/diagnosis , Mycobacterium Infections/drug therapy , Mycobacterium Infections/pathology , Mycobacterium haemophilum/classification , Mycobacterium haemophilum/genetics , Skin Diseases, Bacterial/diagnosis , Skin Diseases, Bacterial/drug therapy , Skin Diseases, Bacterial/pathology
8.
Free Radic Biol Med ; 49(11): 1666-73, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20807564

ABSTRACT

Mycobacterium abscessus infections, particularly those causing chronic lung diseases, are becoming more prevalent worldwide. M. abscessus infections are difficult to treat because of antibiotic resistance. Thus, new treatment options are urgently needed. M. abscessus is an intracellular pathogen that primarily infects macrophages and fibroblasts. Because this bacterium has only recently been identified as a separate species, very little is known about M. abscessus-host interactions and how M. abscessus growth is regulated. Oxidative stress has long been shown to inhibit the growth of bacterial organisms. However, some intracellular bacteria, such as Mycobacterium tuberculosis, grow well in oxidizing environments. In this study, we show that M. abscessus infection causes the host cell environment to become more oxidizing. Furthermore, we show that a more oxidizing environment leads to enhanced growth of M. abscessus inside macrophages. In the presence of antioxidants, MnTE-2-PyP (chemical name: manganese(II) meso-tetrakis-(N-methylpyridinium-2-yl) porphyrin) or N-acetyl-l-cysteine, M. abscessus growth is inhibited. These results lead us to postulate that antioxidants may aid in the treatment of M. abscessus infections.


Subject(s)
Mycobacterium/growth & development , Oxidative Stress/physiology , Acetylcysteine/pharmacology , Anti-Bacterial Agents/pharmacology , Catalase/metabolism , Cells, Cultured , Dose-Response Relationship, Drug , Down-Regulation , Drug Evaluation, Preclinical , Environment , Enzyme Activation , Free Radical Scavengers/pharmacology , Gene Expression Regulation, Enzymologic , Glutathione Peroxidase/metabolism , Humans , Mycobacterium/drug effects , Mycobacterium/physiology , Mycobacterium Infections/genetics , Mycobacterium Infections/metabolism , Mycobacterium Infections/microbiology , Mycobacterium Infections/pathology , Oxidation-Reduction , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolism
9.
Arthritis Rheum ; 62(7): 2160-9, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20506183

ABSTRACT

OBJECTIVE: In rheumatoid arthritis (RA), pain and joint destruction are initiated and propagated by the production of proinflammatory mediators. Synthesis of these mediators is regulated by the transcription factor NF-kappaB, which is controlled by the ubiquitin proteasome system (UPS). The present study explored the effects of the proteasome inhibitor MG132 on inflammation, pain, joint destruction, and expression of sensory neuropeptides as markers of neuronal response in a rat model of arthritis. METHODS: Arthritis was induced in rats by injection of heat-killed Mycobacterium butyricum. Arthritis severity was scored, and nociception was evaluated by mechanical pressure applied to the hind paw. Joint destruction was assessed by radiologic and histologic analyses. NF-kappaB DNA-binding activity was analyzed by electromobility shift assay, and changes in the expression of the p50 NF-kappaB subunit and the proinflammatory neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) were detected by immunohistochemistry. RESULTS: Arthritic rats treated with MG132 demonstrated a marked reduction in inflammation, pain, and joint destruction. The elevated DNA-binding activity of the NF-kappaB/p50 homodimer and p50, as well as the neuronal expression of SP and CGRP, observed in the ankle joints of arthritic rats were normalized after treatment with MG132. CONCLUSION: In arthritic rats, inhibition of proteasome reduced the severity of arthritis and reversed the pain behavior associated with joint inflammation. These effects may be mediated through the inhibition of NF-kappaB activation and may possibly involve the peripheral nervous system. New generations of nontoxic proteasome inhibitors may represent a novel pharmacotherapy for RA.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Arthritis, Experimental/drug therapy , Arthritis, Infectious/drug therapy , Cysteine Proteinase Inhibitors/pharmacology , Leupeptins/pharmacology , Mycobacterium Infections/drug therapy , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Arthritis, Infectious/metabolism , Arthritis, Infectious/pathology , Biomarkers/metabolism , Bone Density/drug effects , Calcitonin Gene-Related Peptide/metabolism , DNA/metabolism , Female , Joints/drug effects , Joints/metabolism , Joints/pathology , Mycobacterium/immunology , Mycobacterium Infections/metabolism , Mycobacterium Infections/pathology , NF-kappa B/metabolism , Pain/prevention & control , Pain Measurement , Pain Threshold/drug effects , Rats , Rats, Inbred Lew , Substance P/metabolism
10.
Emerg Infect Dis ; 12(5): 821-3, 2006 May.
Article in English | MEDLINE | ID: mdl-16704844

ABSTRACT

Nontuberculous mycobacteria, which are widespread in the environment, frequently cause opportunistic infections in immunocompromised patients. We report the first case of a patient with chronic granulomatous dermatitis caused by a rarely described organism, Mycobacterium intermedium. The infection was associated with exposure in a home hot tub.


Subject(s)
Dermatitis/diagnosis , Hydrotherapy/adverse effects , Mycobacterium Infections/diagnosis , Mycobacterium/isolation & purification , Water Microbiology , Dermatitis/microbiology , Dermatitis/pathology , Granuloma/diagnosis , Granuloma/microbiology , Granuloma/pathology , Humans , Immunocompromised Host , Male , Middle Aged , Mycobacterium/genetics , Mycobacterium Infections/pathology
11.
J Infect Chemother ; 7(3): 186-90, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11810582

ABSTRACT

Mycobacterium haemophilum has been described as a pathogen that causes cutaneous lesions in immunocompromised patients. A specimen from a skin ulcer on the leg of a Japanese patient with acquired immunodeficiency syndrome yielded acid-fast bacilli on blood agar plates after 4 weeks of incubation at 30 degrees C, but the organism was not found on Ogawa egg slants. The organism was identified as M. haemophilum, on the basis of 16S rRNA gene sequence analysis. Prolonged culture in an optimal environment that includes an iron supplement, and growth temperatures at 28 degrees to 33 degrees C are necessary to grow M. haemophilum. Genotypic characterization of 16S rRNA is useful for a rapid diagnosis of this slowly growing mycobacterium.


Subject(s)
AIDS-Related Opportunistic Infections/microbiology , Leg Ulcer/microbiology , Mycobacterium Infections/microbiology , Mycobacterium haemophilum/isolation & purification , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/pathology , Base Sequence , DNA, Bacterial , Humans , Japan , Leg Ulcer/drug therapy , Leg Ulcer/pathology , Male , Middle Aged , Molecular Sequence Data , Mycobacterium Infections/drug therapy , Mycobacterium Infections/pathology , Mycobacterium haemophilum/classification , Mycobacterium haemophilum/genetics , Mycobacterium haemophilum/growth & development , RNA, Bacterial/analysis , RNA, Ribosomal, 16S/analysis , Sequence Homology, Nucleic Acid , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL